甾体激素受体共激活因子在 T 细胞和癌症中的作用：对癌症免疫治疗的启示。
Function of Steroid Receptor Coactivators in T Cells and Cancers: Implications for Cancer Immunotherapy.
机构信息
Department of Immunology & Theranostics, Arthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA.
Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, 91010, USA.
出版信息
Crit Rev Immunol. 2024;44(6):111-126. doi: 10.1615/CritRevImmunol.2024051613.
Steroid receptor coactivator (SRC) family members (SRC1, SRC2 and SRC3) are transcriptional co-regulators. SRCs orchestrate gene transcription by inducing transactivation of nuclear receptors and other transcription factors. Overexpression of SRCs is widely implicated in a range of cancers, especially hormone-related cancers. As coactivators, SRCs regulate multiple metabolic pathways involved in tumor growth, invasion, metastasis, and chemo-resistance. Emerging evidence in recent years suggest that SRCs also regulate maturation, differentiation, and cytotoxicity of T cells by controlling metabolic activities. In this review, we summarize the current understanding of the function of SRCs in T cells as well as cancer cells. Importantly, the controversies of targeting SRCs for cancer immunotherapy as well as possible reconciliation strategies are also discussed.
类固醇受体共激活因子（SRC）家族成员（SRC1、SRC2 和 SRC3）是转录共激活因子。SRC 可通过诱导核受体和其他转录因子的反式激活来协调基因转录。SRC 的过表达广泛涉及多种癌症，尤其是激素相关癌症。作为共激活因子，SRC 调节参与肿瘤生长、侵袭、转移和化疗耐药的多种代谢途径。近年来的新证据表明，SRC 通过控制代谢活动也调节 T 细胞的成熟、分化和细胞毒性。在这篇综述中，我们总结了目前对 SRC 在 T 细胞和癌细胞中的功能的理解。重要的是，还讨论了针对癌症免疫治疗靶向 SRC 的争议以及可能的调和策略。
Zotero 插件